SFA Therapeutics Completes Enrollment for Phase 1b Psoriasis Trial of SFA-002
JENKINTOWN, Pa., May 30, 2024 – SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced the successful completion of patient enrollment for the second cohort of its Phase 1b clinical trial of SFA-002, an oral small molecule biosynthetic compound aimed at treating mild-to-moderate chronic plaque psoriasis.
Dr. Stefan Weiss, Chief Medical Officer at SFA Therapeutics, emphasized the significance of this milestone in assessing the safety and efficacy of SFA-002. He pointed out that SFA-002, being an endogenous biosynthetic compound, holds potential as a disease-modifying treatment targeting multiple pathways, potentially offering enhanced efficacy and fewer side effects for patients suffering from psoriasis.
As the Phase 1b trial nears its conclusion, SFA Therapeutics is preparing to advance to Phase 2 studies in the latter half of the year. Ira Spector, Chief Executive Officer of SFA Therapeutics, expressed optimism regarding the positive topline and safety results from the first cohort of the Phase 1b trial, which underscore the potential of SFA-002 as an effective treatment for psoriasis. Spector anticipates additional data from both the first and second cohorts in the upcoming months.
Previously, SFA Therapeutics reported encouraging results from the first cohort of its Phase 1b trial, which included 14 subjects with challenging cases of scalp psoriasis and palmoplantar psoriasis. Notably, 92% of evaluable patients exhibited a PASI (Psoriasis Area and Severity Index) improvement exceeding 50%, with 72% achieving an improvement greater than PASI 75. Remarkably, two patients achieved 100% clearance (PASI 100). Importantly, no adverse events or toxicities related to the treatment were observed, and no rebound effects were noted during the treatment period and follow-up.
About SFA Therapeutics
SFA Therapeutics, Inc., located in Jenkintown, Pennsylvania, is a clinical-stage biopharmaceutical firm focused on developing oral small molecule biosynthetic compounds for treating inflammatory diseases. The company’s innovative approach, based on research licensed from Temple University, aims to create safer and more effective treatments for various chronic inflammatory diseases by customizing the effects of patented formulations with target-specific adjuvants.
SFA-002, the company's primary asset, has shown promising results in Phase 1a and Phase 1b trials for psoriasis and is on the verge of entering Phase 2 clinical trials. Additionally, SFA Therapeutics has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to study SFA-001N in patients with metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), with or without fibrosis. Furthermore, the FDA has granted Orphan Disease Designation to SFA-001 for treating hepatocellular carcinoma, the most common type of liver cancer.
The company's commitment to advancing treatment options for inflammatory diseases is underscored by its dedication to developing innovative therapeutics that offer improved safety and efficacy profiles. As SFA Therapeutics continues its research and development efforts, the upcoming Phase 2 trials of SFA-002 for psoriasis represent a significant step forward in providing new hope for patients with this chronic condition.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
